Risultati per: Nuovo test del sangue per la diagnosi di cancro alla prostata

Per tumori in stadio 1 per la guarigione basta un anno. Favo, possibili tempi più brevi per l’oblio oncologico

Indispensabile intervenire per correggere gli stili di vita e intercettare i fattori prodromici che favoriscono la cancerogenesi

Presentata campagna Pfizer ed Europa Uomo ‘Men’s Pro’

Sperimentale e terapeutico, è basato su Rna

Sarà sfruttata la sensoristica all’avanguardia insieme all’intelligenza artificiale.

Lancet, prepararsi a gestire il fenomeno

Da maggio, è dedicata alla raccolta del 5 per mille

Allarme di Lancet, prepararsi a gestire il fenomeno

Introduction
Chimeric antigen receptor (CAR) T-cell therapies are novel, potentially curative therapies for haematological malignancies. CAR T-cell therapies are associated with severe toxicities, meaning patients require monitoring during acute and postacute treatment phases. Electronic patient-reported outcomes (ePROs), self-reports of health status provided via online questionnaires, can complement clinician observation with potential to improve patient outcomes. This study will develop and evaluate feasibility of a new ePRO system for CAR-T patients in routine care.

Methods and analysis
Multiphase, mixed-methods study involving multiple stakeholder groups (patients, family members, carers, clinicians, academics/researchers and policy-makers). The intervention development phase comprises a Delphi study to select PRO measures for the digital system, a codesign workshop and consensus meetings to establish thresholds for notifications to the clinical team if a patient reports severe symptoms or side effects. Usability testing will evaluate how users interact with the digital system and, lastly, we will evaluate ePRO system feasibility with 30 CAR-T patients (adults aged 18+ years) when used in addition to usual care. Feasibility study participants will use the ePRO system to submit self-reports of symptoms, treatment tolerability and quality of life at specific time points. The CAR-T clinical team will respond to system notifications triggered by patients’ submitted responses with actions in line with standard clinical practice. Feasibility measures will be collected at prespecified time points following CAR T-cell infusion. A qualitative substudy involving patients and clinical team members will explore acceptability of the ePRO system.

Ethics and dissemination
Favourable ethical opinion was granted by the Health and Social Care Research Ethics Committee B(HSC REC B) (ref: 23/NI/0104) on 28 September 2023. Findings will be submitted for publication in high-quality, peer-reviewed journals. Summaries of results, codeveloped with the Blood and Transplant Research Unit Patient and Public Involvement and Engagement group, will be disseminated to all interested groups.

Trial registration number
ISCTRN11232653.

‘Spesso sono forme lievi non diagnosticate in età infantile’

Il 70% dei pazienti oncologici trova informazioni errate sui social

Oncologi, nuove cure e esami specifici migliorano sopravvivenza

Current test performance characteristics of blood-based colorectal cancer screening tests are insufficient to justify their high costs compared with less expensive and more effective alternatives such as fecal immunochemical testing, triennial stool DNA testing combined with a fecal immunochemical testing assay, and colonoscopy.